Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue

Abstract

Purpose: To develop and validate a population pharmacokinetic model for troxacitabine, a novel L-nucleoside analogue, administered by short infusion; to characterize clinical covariates that influence pharmacokinetic variability; and to design a dosage rate for continuous infusion administration to achieve low micromolar concentrations, which may be more efficacious than shorter infusions. Experimental Design: Plasma samples from 111 cancer patients receiving troxacitabine (0.12-12.5 mg/m 2 ) as a 30-minute infusion in phase I trials were used to develop the model with NONMEM. Clinical covariates evaluated included creatinine clearance, body surface area, age, and sex. From the model, a troxacitabine dosage rate of 2.0 to 3.0 mg/m 2 /d was expected to achieve a target concentration of 0.1 Amol/L; plasma samples were obtained during the infusion from eight patients receiving troxacitabine as a 3-day infusion. Results:Troxacitabine pharmacokinetics were characterized by a three-compartment linear model. The mean value for systemic clearance [interindividual variability (CV%)] from the covariatefree model was 9.1 L/h (28%). Creatinine clearance and body surface area accounted for 36% of intersubject variation in clearance. Troxacitabine 2.0 mg/m 2 /d (n = 3) and 3.0 mg/m 2 /d (n = 5) for 3 days produced mean F SD end of infusion concentrations of 0.12 F 0.03 and 0.15 F 0.03 Amol/L, respectively. Conclusions: Renal function and body surface area were identified as sources of troxacitabine pharmacokinetic variability. The population pharmacokinetic model model^derived dosage rates for continuous infusion administration successfully achieved predetermined target plasma concentrations.The present model may be used to optimize treatment with troxacitabine by developing a dosing strategy based on both renal function and body size.

Encouraging the Move Towards Predictive Population Models for the Obese Using Propofol as a Motivating Example

“…Indeed, various PK studies in adults have identified a nonlinear relationship between drug CL and TBW for both hepatic and renally eliminated drugs, supporting the LBW hypothesis (6)(7)(8)(9)(10)(11)(12). In studies where LBW was not considered as a covariate, the curvilinear relationship has often been accounted for by the inclusion of covariates such as body surface area (BSA), TBW with an allometric coefficient (either fixed to ¾ or estimated), or inclusion of empirically derived body composition metrics such as 'PK mass' (12).…”

Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice

“…Population pharmacokinetics of many anticancer agents are currently being investigated as a part of clinical development; ( 25–31 ) however, unfit patients, including those with organ dysfunction or poor performance status, are commonly excluded from clinical trials, resulting in a paucity of pharmacokinetic information for these groups. After drugs are approved, however, these patients are treated in medical practice, and dose reduction may be required at the discretion of attending physicians.…”

Preparation and evaluation of [125I]troxacitabine: L‐nucleoside model of a potential agent for tumor diagnosis and radiotherapy

“…Ehrlich tumor mouse model is a widely used useful model for preclinical evaluation of novel therapeutics 3, 17, 18. Troxacitabine pharmacokinetics19 is characterized by a three compartment phase linear model. Troxacitabine has a long terminal half‐life (82 h) and a systemic clearance comparable to the glomerular filtration rate (137 ml/min).…”